secwatch.observer — SEC 8-K summary
======================================

Issuer:     ACTUATE THERAPEUTICS, INC. (ACTU)
CIK:        0001652935
Form:       8-K
Filed at:   2026-05-06T23:59:59+00:00
Accession:  0001683168-26-003515
Event type: leadership
Sentiment:  positive
Materiality: 0.50
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Actuate Therapeutics appoints former Mersana CEO Martin Huber to board
----------------------------------------------------------------------

- Board expanded from 7 to 8; Huber appointed as Class III director effective May 1, 2026.
- Huber previously President/CEO of Mersana until Jan 2026 acquisition by Day One Biopharmaceuticals.
- Receives initial option grant of 30,000 shares (3-year vest), annual retainer $44,000, plus $3,000/quarter consulting fee.
- He will serve on Nominating and Corporate Governance Committee; expertise includes approvals of pembrolizumab, niraparib, others.
- Company highlights his role in advancing elraglusib for difficult-to-treat cancers including metastatic pancreatic cancer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1652935/000168316826003515/0001683168-26-003515-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1652935/000168316826003515/actuate_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-26-003515

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer